Insulet Corp Stock Price, News & Analysis

Insulet Corporation (NASDAQ: PODD) has received FDA clearance for its Omnipod® 5 Automated Insulin Delivery System, aimed at individuals aged six and older with type 1 diabetes. This system is the first tubeless automated insulin delivery technology that integrates with the Dexcom G6 Continuous Glucose Monitoring system, allowing automatic insulin adjustments to help manage blood sugar levels effectively. Omnipod 5 will be launched through pharmacies, with a limited market release planned to gather insights for product enhancement.

Insulet Corporation (NASDAQ: PODD) will announce its fourth quarter and full year financial results for 2021 on February 23, 2022, after market close. A conference call with management is scheduled for 4:30 p.m. ET on the same day. The call will be accessible through the Investor Relations section of the company's website, and a replay will be available post-event. Insulet specializes in tubeless insulin pump technology under its Omnipod brand, offering innovative solutions for diabetes management and expanding to deliver non-insulin medications.

Insulet Corporation (NASDAQ: PODD) announced its participation in the 45th Nasdaq Investor Conference on December 3, 2021, at 11:30 a.m. ET. The presentation will be held virtually, and investors can access the live webcast at investors.insulet.com/events, with a replay available post-event. Insulet is renowned for its tubeless insulin pump technology through its Omnipod product line, focusing on simplifying diabetes management with its innovative, needle-free delivery system.

Insulet Corporation (NASDAQ: PODD) reported strong third-quarter results for the period ending September 30, 2021, with revenues of $275.6 million, reflecting a 17.8% year-over-year increase. Notably, Omnipod revenue surged to $260.3 million, a growth of 22.7%. Operating income reached $33.7 million with a gross margin of 68.5%. Despite a 30.1% decline in Drug Delivery revenue, net income rose to $12.6 million. The company also updated its revenue guidance for the year to 18%-20% growth and confirmed a low double-digit operating margin expectation.

Insulet Corporation (NASDAQ: PODD) has appointed Luciana Borio, M.D., to its Board of Directors, bringing extensive government and public health experience. Dr. Borio has held significant roles at the FDA and National Security Council, specializing in medical product development and biodefense. Her expertise is expected to enhance Insulet's growth strategy. Additionally, Sally W. Crawford will retire from the Board effective December 31, 2021, after 13 years of service, with gratitude expressed for her contributions.

Insulet Corporation (NASDAQ: PODD) reported positive results from its pivotal trial extension for the Omnipod 5 Automated Insulin Delivery System, demonstrating significant improvements in diabetes management for users aged 6-70. Over 12 months, participants showed sustained reductions in HbA1c, with adults decreasing from 7.2% to 6.8% and children from 7.7% to 7.0%. Additionally, time in range increased notably. Insulet also presented data on the Omnipod DASH, highlighting a decrease in hypoglycemic events. The Omnipod 5 is expected to launch in the US in late Q4 2021.

Insulet Corporation (NASDAQ: PODD) announced its plan to release third quarter financial results on November 4, 2021, after market close. Management will hold a conference call at 4:30 p.m. ET to discuss the results. Insulet is known for its innovative Omnipod insulin management system, which offers a needle-free, wearable insulin delivery option. The company aims to simplify life for people with diabetes through its unique product platform. Investors can access the call via the company's Investor Relations website.